Centers for Disease Control and Prevention

Description

The purpose of the project is to evaluate the clinical laboratory best practice recommendation for reducing blood sample hemolysis rates developed through the Laboratory Medicine Best PracticesTM (LMBPTM) Initiative of the Centers for Disease Control and Prevention. This recommendation was the product of a systematic review for evidence of effectiveness for practices to reduce hemolysis and was developed using the A6 Method established through the LMBPTM Initiative. The current study seeks to measure the extent of improvement that results from implementation of this evidence-based best practice recommendation compared to existing (current) practices to reduce hemolysis. The design of the recommendation evaluation plan should be based on the A6 Method, described elsewhere in this document, and consider evidence of effectiveness as defined by laboratory quality indicators, patient outcomes, and cost analyses consistent with national health care priorities for improving public health. The LMBPTM recommendation for reduction of blood sample hemolysis rates will be evaluated through replication as described. One applicant will be awarded. This single award can be implemented as a study conducted in a single institution, measuring one or more settings within the institution, or multiple settings within affiliated facilities of a health system. The budget should reflect study design complexity. The purpose is limited to quality improvement associated with delivering healthcare, and the associated measuring and reporting of performance data.

Who can apply

• Others

Contact

CDC Procurement and Grants Office <br/>(PGO) Technical Information Management Section (TIMS) <br/>Phone: 770-488-2700 <br/>E-mail: pgotim@cdc.gov <br/>
pgotim@cdc.gov